Evidence map›Paper›PMID 24108117›Full record

Trial reportPediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies2013

Functional outcomes in pediatric severe sepsis: further analysis of the researching severe sepsis and organ dysfunction in children: a global perspective trial.

Reid W D Farris, Noel S Weiss, Jerry J Zimmerman

Registry-linked trialAbstract readClinical Trial
In one paragraph

Trial report in Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00049764 (Investigation of the Efficacy and Safety of Drotrecogin Alfa), which is not on this map. Cited by 81 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00049764 phase3completednot on this map

Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis

TypeinterventionalSponsorEli Lilly and CompanyRan2002 to 2005Enrolled474ConditionsSepsisArmsDrotrecogin alfa (activated), Placebo
3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Primary Outcome Measures in Pediatric Septic Shock Trials: A Systematic Review.Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies · 2017
    Pooled it
  2. Long-Term Mortality and Morbidity After Pediatric Sepsis.Open forum infectious diseases · 2026
    Article
  3. Review
  4. Proteomic profiling and pathway analyses reveal molecular signatures and immune networks in pediatric sepsis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Early Mobilization in Pediatric Critical Care: Exploring the Gap Between Theory and Practice in Saudi Arabia.Medical science monitor : international medical journal of experimental and clinical research · 2024
    Article
  13. Article
  14. Observational
  15. Follow-up after PICU discharge for patients with acquired brain injury: the role of an abbreviated neuropsychological evaluation and a return-to-school program.Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies · 2023
    Article
  16. Fluid Balance and Its Association With Mortality and Health-Related Quality of Life: A Nonprespecified Secondary Analysis of the Life After Pediatric Sepsis Evaluation.Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies · 2023
    Article
  17. Article
  18. Review
  19. Article
  20. Review

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Reid W D Farris1Division of Critical Care Medicine, Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA. 2Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA.
Noel S Weiss
Jerry J Zimmerman

Funding

Life After Pediatric Sepsis Evaluation, LAPSER01HD073362 · NICHD · SEATTLE CHILDREN'S HOSPITAL · PI ZIMMERMAN, JERRY JOHN · 2013 to 2017
$3.1M
1st Tier Drugs+Theophylline in Pediatric Severe AsthmaU10HD049945 · NICHD · SEATTLE CHILDREN'S HOSPITAL · PI ZIMMERMAN, JERRY JOHN · 2005 to 2010
$1.6M
NICHD NIH HHS R01 HD073362NICHD NIH HHS U10 HD049945
6 · The paper itself

Abstract

objectivesTo evaluate risk factors for poor functional outcome in 28-day survivors after an episode of severe sepsis.

designRetrospective cohort study examining data from the Researching Severe Sepsis and Organ Dysfunction in Children: A Global Perspective trial (NCT00049764).

settingOne hundred and four pediatric centers in 18 countries. SUBJECTS: Children with severe sepsis who required both vasoactive-inotropic infusions and mechanical ventilation and who survived to 28 days (n = 384).

interventionsNone. MEASUREMENTS AND MAIN

resultsPoor functional outcome was defined as a Pediatric Overall Performance Category score greater than or equal to 3 and an increase from baseline when measured 28 days after trial enrollment. Median Pediatric Overall Performance Category at enrollment was 1 (interquartile range, 1-2). Median Pediatric Overall Performance Category at 28 days was 2 (interquartile range, 1-4). Thirty-four percent of survivors had decline in their functional status at 28 days, and 18% were determined to have a "poor" functional outcome. Hispanic ethnicity was associated with poor functional outcome compared to the white referent group (risk ratio = 1.9; 95% CI: 1.0-3.0). Clinical factors associated with increased risk of poor outcome included CNS and intra-abdominal infection sources compared to the lung infection referent category (risk ratio = 3.3; 95% CI: 1.4-5.6 and 2.4; 95% CI: 1.0-4.5, respectively); a history of recent trauma (risk ratio = 3.9; 95% CI: 1.4-5.4); receipt of cardiopulmonary resuscitation prior to enrollment (risk ratio = 5.1; 95% CI: 2.9-5.7); and baseline Pediatric Risk of Mortality III score of 20-29 (risk ratio = 2.8; 95% CI: 1.2-5.2) and Pediatric Risk of Mortality III greater than or equal to 30 (risk ratio = 4.5; 95% CI: 1.6-8.0) compared to the referent group with Pediatric Risk of Mortality III scores of 0-9.

conclusionsIn this sample of 28-day survivors of pediatric severe sepsis diminished functional status was common. This analysis provides evidence that particular patient characteristics and aspects of an individual's clinical course are associated with poor functional outcome 28 days after onset of severe sepsis. These characteristics may provide opportunity for intervention in order to improve functional outcome in pediatric patients with severe sepsis. Decline in functional status 28 days after onset of severe sepsis is a frequent and potentially clinically meaningful event. Utilization of functional status as the primary outcome in future pediatric sepsis clinical trials should be considered.

Indexed as

Organ Dysfunction ScoresSeverity of Illness IndexAdolescentAnticoagulantsAsian PeopleCardiotonic AgentsCentral Nervous System InfectionsChildChild, PreschoolHispanic or LatinoHumansInfantInfant, NewbornProtein CRespiration, ArtificialRespiratory Tract InfectionsAnticoagulantsCardiotonic AgentsProtein C

Identifiers

PMID24108117
PMCPMC4080839

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.